SPX-305

SPX-305 is a preclinical-stage bispecific antibody candidate developed by SparX Biotech for the treatment of solid tumors. It is part of the company's "SPX-300" series of multi-specific biologics, which are engineered using their proprietary SAILING and SynMab platforms. These platforms utilize optimized antibody libraries and advanced screening techniques to identify synergistic target pairs. While SparX Biotech's official pipeline documentation often lists SPX-305 within a discovery-stage range without specific molecular details, industry reports identify the asset as a bispecific antibody targeting Programmed cell death 1 ligand 1 (PD-L1) and T-cell immunoreceptor with Ig and ITIM domains (TIGIT). The program aims to enhance anti-tumor immune responses by simultaneously blocking two distinct inhibitory checkpoints to overcome resistance in oncology.